Jan Detka, PhD
Hypothalamic insulin and glucagon-like peptide-1 levels in an animal model of depression and their effect on corticotropin-releasing hormone promoter gene activity in a hypothalamic cell line.
Jan Detka, Joanna Ślusarczyk, Anna Kurek, Mateusz Kucharczyk, Tomasz Adamus, Paweł Konieczny, Marta Kubera, Agnieszka Basta-Kaim, Władysław Lasoń, Bogusława Budziszewska
Pharmacological reports : PR, S1734-1140(18)30461-4 10.1016/j.pharep.2018.11.001
The reduced level of growth factors in an animal model of depression is accompanied by regulated necrosis in the frontal cortex but not in the hippocampus.
Mateusz Kucharczyk, Anna Kurek, Bartosz Pomierny, Jan Detka, Mariusz Papp, Katarzyna Tota, Bogusława Budziszewska
Psychoneuroendocrinology, S0306-4530(17)31488-9 10.1016/j.psyneuen.2018.05.008
Regulators of glucocorticoid receptor function in an animal model of depression and obesity.
Anna Kurek, Katarzyna Głombik, Jan Detka, Agnieszka Basta-Kaim, Marta Kubera, Władysław Lasoń, Bogusława Budziszewska
Journal of neuroendocrinology, 10.1111/jne.12591
The effects of pessimism on cell-mediated immunity in rats.
Katarzyna Curzytek, Marta Kubera, Ewa Trojan, Kinga Wójcik, Agnieszka Basta-Kaim, Jan Detka, Michael Maes, Rafal Rygula
Progress in neuro-psychopharmacology & biological psychiatry, S0278-5846(17)30059-3 10.1016/j.pnpbp.2017.04.034
Suppression of pro-inflammatory cytokine expression and lack of anti-depressant-like effect of fluoxetine in lipopolysaccharide-treated old female mice.
Weronika Duda, Marta Kubera, Grzegorz Kreiner, Katarzyna Curzytek, Jan Detka, Katarzyna Głombik, Joanna Ślusarczyk, Agnieszka Basta-Kaim, Bogusława Budziszewska, Władysław Lasoń, Magdalena Regulska, Monika Leśkiewicz, Adam Roman, Agnieszka Zelek-Molik, Irena Nalepa
International immunopharmacology, S1567-5769(17)30155-8 10.1016/j.intimp.2017.04.021
The influence of glucagon-like peptie-1 receptor agaonists on regulation of coticotropin-releasing hormone gene promoter activity UMO-2012/07/N/NZ7/04394 - 2013-07-04 - 2017-04-03
The aim of the project is to determine the effect of glucagon-like peptide-1 receptor (GLP-1R) agonists, used to treat type 2 diabetes on the regulation of corticoliberin (CRH) gene expression. Many reports have indicated a distinct role of GLP-1 as a brain modulator of neuroendocrine processes, emphasizing its implication in hypothalamic-pituitary-adrenal (HPA) axis activation. Considering that chronic HPA axis activation is thought to be an important factor in the pathogenesis of depression which can also stimulate type 2 diabetes development in some depressed patients, it is necessary to better understand GLP-1 involvement in hormonal regulation in the organism and its action in the hypothalamus. Numerous papers suggest GLP-1 involvement in the activation of hypothalamic paraventricular neurons and most recent reports indicate its influence on CRH expression in transiently transfected neuronal cell line. However, so far the effect of GLP-1 on CRH gene expression was not studied in terms protein kinase A activation (main pathway of CRH activation in stress) or attenuation of CRH gene activity by glucocorticoids. It is also undetermined if the potential effect of GLP-1 in the hypothalamus depends on insulin, as well as nobody studied the cellular mechanisms, involved in the following processes.
- forced swim test
- immobilisation stress
- immune cells tissue cultures
- in vitro transfection
- mammalian cells tissue cultures
- MTT test
- novel obiect recognition
- protein fractioning
- radiologand binding
- Real Time PCR
- tissue cultures with stable expressing genes encoding selected proteins
- Western Blot